Ovarian Cancer Drugs Global Markets Report 2021: Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR inhibitors, PARP inhibitors, Antineoplastics – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ovarian Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030” report has been added to ResearchAndMarkets.com’s offering.

Major players in the ovarian cancer drugs market are AstraZeneca, Roche, Tesaro, Clovis Oncology, and Boehringer Ingelheim.

The global ovarian cancer drugs market is expected to grow from $1.49 billion in 2020 to $1.73 billion in 2021 at a compound annual growth rate (CAGR) of 16.1%.

The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges.

The market is expected to reach $3.51 billion in 2025 at a CAGR of 19.3%.

The ovarian cancer drugs market consists of sales of ovarian cancer drugs to treat ovarian cancer. Ovarian cancer is caused due to abnormal growth of cells in ovary. This industry includes establishments that produce drugs used in chemotherapy, radiation, and surgery for treating ovarian cancer.

The ovarian cancer drugs include Paclitaxel, Cisplatin, Adriamycin PFS (Doxorubicin Hydrochloride), Carboplatin, Cyclophosphamide, Platinol (Cisplatin), Paraplatin (Carboplatin), Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Cytoxan (Cyclophosphamide), Paraplat (Carboplatin), Taxol (Paclitaxel), Neosar (Cyclophosphamide) and others.

In January 2019, GlaxoSmithKline (GSK), a UK-based pharmaceutical company, acquired Tesaro for $5.1 billion. This acquisition would enable GSK to expand its product portfolio with Tesaro’s Zejula, PARP inhibitor and others, improve significant opportunities in strengthening GSK’s pharmaceutical business by accelerating the build of GSK’s pipeline and commercial capability in oncology.

Tesaro, a biopharmaceutical (oncology-focused) company, is involved in manufacturing and marketing ovarian cancer drugs such as Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor and others, that aid in treating ovarian cancer. Tesaro was founded in 2010 and headquartered in Waltham, Massachusetts, USA.

The rising incidence of ovarian cancer is driving the ovarian cancer drugs market. Furthermore, ovarian cancer is recorded to be the eighth most commonly occurring cancer in women and the 18th most commonly occurring cancer across the globe. According to a study by The World Ovarian Cancer Coalition an estimated 55% rise is expected in the number of patients suffering from ovarian cancer by 2035. According to the Cancer Statistics in 2020, published by the American Cancer Society’, about 1,806,590 new cancer cases and 606,520 deaths were expected in USA. Thus, the increasing incidence of ovarian cancer cases across the globe drives the ovarian cancer drugs market growth.

Drug manufacturing companies in the industry are increasingly innovating and developing combination drugs to treat ovarian cancer drugs. Combination drugs consists of two or more active pharmaceutical ingredients (APIs) that are combined into a single dosage form to treat complex medical conditions.

The pharmaceutical companies in the ovarian cancer drugs market are investing on the research and development of innovative products such as combination drugs to reduce manufacturing costs, increase compliance and efficiency, improve medication concordance, increase profitability and reduce side effects. For instance, Roche’s blockbuster tranquilize Avastin (bevacizumab), is a combination drug approved by FDA, with ingredients such as carboplatin and paclitaxel, which is utilized to treat advance stage (III or IV) ovarian cancer.

Key Topics Covered:

1. Executive Summary

2. Ovarian Cancer Drugs Market Characteristics

3. Ovarian Cancer Drugs Market Trends And Strategies

4. Impact Of COVID-19 on Ovarian Cancer Drugs

5. Ovarian Cancer Drugs Market Size And Growth

5.1. Global Ovarian Cancer Drugs Historic Market, 2015-2020, $ Billion

5.1.1. Drivers of the Market

5.1.2. Restraints on The Market

5.2. Global Ovarian Cancer Drugs Forecast Market, 2020-2025F, 2030F, $ Billion

5.2.1. Drivers of the Market

5.2.2. Restraints on the Market

6. Ovarian Cancer Drugs Market Segmentation

6.1. Global Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

• Epithelial Ovarian Cancer
• Ovarian Low Malignant Potential Tumor
• Germ Cell Tumor
• Sex Cord-Stromal Tumor

6.2. Global Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

• Hospital Pharmacies
• Drug Stores
• Others

6.3. Global Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

• Alkylating Agents
• Mitotic Inhibitors
• Antirheumatics
• Antipsoriatics
• VEGF/VEGFR inhibitors
• PARP inhibitors
• Antineoplastics
• Others

7. Ovarian Cancer Drugs Market Regional And Country Analysis

7.1. Global Ovarian Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7.2. Global Ovarian Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

• AstraZeneca
• Roche
• Tesaro
• Clovis Oncology
• Boehringer Ingelheim
• Amgen
• GlaxoSmithKline
• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• Johnson & Johnson
• Merck KGaA
• Syndax Pharmaceuticals
• Allergan plc
• Celgene
• Janssen Pharmaceuticals
• Novogen
• Genentech
• Aetera Zenteris
• AbbVie
• ImmunoGen
• Oasmia Pharmaceuticals
• Spectrum Pharmaceuticals
• Abraxane
• DelMar Pharmaceuticals Inc
• Alkeran
• Novartis

For more information about this report visit https://www.researchandmarkets.com/r/qviypv

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900